Temporal Effect on PD‐L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer

Eitemau Tebyg

• The rapidly changing field of predictive biomarkers of non-small cell lung cancer
  gan: László József Tóth, et al.
  Cyhoeddwyd: (2024-06-01)
• Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
  gan: Akram Alwithenani, et al.
  Cyhoeddwyd: (2021-01-01)
• Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
  gan: Jianing Chen, et al.
  Cyhoeddwyd: (2022-08-01)
• Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
  gan: Shayista Akbar, et al.
  Cyhoeddwyd: (2023-01-01)
• Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade
  gan: Wang L, et al.
  Cyhoeddwyd: (2024-09-01)